Shares of Akari Therapeutics, Plc (NASDAQ:AKTX – Get Free Report) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.72 and traded as low as $2.21. Akari Therapeutics shares last traded at $2.27, with a volume of 17,467 shares changing hands.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on shares of Akari Therapeutics in a report on Friday. They issued a “sell” rating on the stock.
Read Our Latest Report on Akari Therapeutics
Akari Therapeutics Stock Up 4.2 %
Akari Therapeutics Company Profile
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
Featured Articles
- Five stocks we like better than Akari Therapeutics
- What Are Dividend Contenders? Investing in Dividend Contenders
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Manufacturing Stocks Investing
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- 10 Best Airline Stocks to Buy
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
